The ubiquitin proteasome pathway was discovered in the 1980s to be a central component
of the cellular protein-degradation machinery with essential functions in homeostasis, which …

Over the past ten years, proteasome inhibition has emerged as an effective therapeutic
strategy for treating multiple myeloma (MM) and some lymphomas. In 2003, Bortezomib …

Proteasome inhibitor (PI) resistance mechanisms in multiple myeloma (MM) remain
controversial. We report the existence of a progenitor organization in primary MM that …

For many decades classical anti-tumor therapies included chemotherapy, radiation and
surgery; however, in the last two decades, following the identification of the genomic drivers …

Over the past decade, the proteasome inhibitor bortezomib (Velcade) has not only gained a
cornerstone position in the treatment of hematological malignancies, particularly multiple …

Despite an increasing number of approved therapies, multiple myeloma (MM) remains an
incurable disease and only a small number of patients achieve prolonged disease control …

Proteasome inhibition with bortezomib is a validated approach to the treatment of multiple
myeloma, but drug resistance often emerges and limits its utility in the retreatment setting. To …

Proteasome inhibition is a novel treatment for several hematological malignancies.
However, resistance to the proteasome inhibitor bortezomib (BTZ, Velcade) is an emerging …

The proteasome inhibitor, bortezomib, a boronic dipeptide which reversibly inhibit the
chymotrypsin-like activity at the β5-subunit of proteasome (PSMB5), has marked efficacy …

Proteasome inhibitors have shown relevant clinical activity in several hematological
malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient …